Recombinant CD40L (Ruplizumab Biosimilar) 抗体
Our Local Distributor
北京 101111
Quick Overview for Recombinant CD40L (Ruplizumab Biosimilar) 抗体 (ABIN5564228)
抗原
抗体类型
适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
原理
- anti-CD40L (human), mAb (rec.) (blocking) (hu5c8) (preservative free)
-
特异性
- Recognizes and binds human CD40L with an IC50 of 0.845 μg/mL. Cross-reacts with canine CD40L.
-
交叉反应 （详细）
- Cross-reacts with canine CD40L.
-
产品特性
- Recombinant Antibody. Recognizes and binds human CD40L with an IC50 of 0.845 μg/mL. Cross-reacts with canine CD40L. Species cross-reactivity: Dog, Human. Clone: hu5c8. Isotype: Human IgG1kappa. Applications: FACS, FUNC, FUNC (Blocking), WB. Host: . Liquid. In PBS. CD40 Ligand (CD40L), renamed TNFSF5 but now also known as CD154, TRAP and gp39, is a 34-39 kDa type II transmembrane glycoprotein, that belongs to the TNF superfamily, and a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. CD40L binds to CD40, which is essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development and germinal center formation. CD40 is constitutively expressed by antigen presenting cells, including dendritic cells, B cells and macrophages. Consistent with its widespread expression on normal cells, CD40 is also expressed on a wide range of tumor cells. CD40L levels are increased in serum and in inflamed tissues of patients with autoimmune diseases.
-
纯度
- >95 % (SDS-PAGE)
-
内毒素水平
- <0.001EU/μg
-
免疫原
- Recombinant human CD40L.
-
亚型
- IgG1 kappa
-
-
anti-CD40LG (Ruplizumab Biosimilar) antibody
Research Grade 适用: 人 FACS, ELISA 宿主: Humanized Monoclonal unconjugated Recombinant Antibody
anti-CD40LG (Ruplizumab Biosimilar) antibody适用: 人 FACS, WB, BR 宿主: Human Monoclonal hu5c8 unconjugated Recombinant Antibody
anti-CD40LG (Ruplizumab Biosimilar) antibody适用: 人 FACS, WB, BR 宿主: 兔 Chimeric hu5c8 unconjugated Recombinant Antibody
-
-
说明
-
This antibody is a biosimilar called Ruplizumab (Antova, BG9588) and originally developed by Biogen. Ruplizumab is a CD40 ligand blocker designed for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis, but withdrawn from clinical trials due to side effects.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 mg/mL
-
缓冲液
- In PBS.
-
储存液
- Without preservative
-
注意事项
- Avoid freeze/thaw cycles.
-
储存条件
- 4 °C,-20 °C
-
储存方法
-
+4°C
-20°C
Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C.
-
有效期
- 12 months
-
-
- CD40L (Ruplizumab Biosimilar) (CD40LG (Ruplizumab Biosimilar))
-
别名
- CD40L (Ruplizumab Biosimilar)
-
物质类
- Biosimilar
-
背景
-
Alternate Names/Synonyms: CD40 Ligand, CD154, Tumor Necrosis Factor Ligand Superfamily Member 5,TNFSF5, Gp39, TRAP
Product Description: CD40 Ligand (CD40L), renamed TNFSF5 but now also known as CD154, TRAP and gp39, is a 34-39 kDa type II transmembrane glycoprotein, that belongs to the TNF superfamily, and a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. CD40L binds to CD40, which is essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development and germinal center formation. CD40 is constitutively expressed by antigen presenting cells, including dendritic cells, B cells and macrophages. Consistent with its widespread expression on normal cells, CD40 is also expressed on a wide range of tumor cells. CD40L levels are increased in serum and in inflamed tissues of patients with autoimmune diseases.
-
UniProt
- P29965
抗原
-
